http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3593144-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b99e2c723498fb91a5f3957b9560a17a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2018-03-12^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c039c3282a1685b8439bf64dbe7d110 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_382d916362516c34bd03121e6e00e530 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6727816c6cfe34d9bb1c4b7335c4340c |
| publicationDate | 2020-01-15^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3593144-A1 |
| titleOfInvention | Method relating to myostatin pathway inhibition |
| abstract | The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising : (a) determining a level of myostatin and/or activin type II receptor (ActRII) and/or follistatin in at least one muscle biopsy obtained from a treatment target muscle in a subject having or suspected of having muscle atrophy or a muscle wasting condition; and (b) determining a level of myostatin and/or follistatin in a systemic sample obtained from the patient, wherein if: (i) the level of myostatin in the systemic sample is higher than a threshold and/or if the level of follistatin in the sample is lower than a threshold; and (ii) the level of myostatin and/or ActRII receptor in the at least one biopsy sample is higher than a threshold level and/or if the level of follistatin in the at least one biopsy sample is lower than a threshold level, the patient will respond to treatment. |
| priorityDate | 2017-03-10^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 515 of 515.